araag2/HINT huggingface dataset:
Clinical trial NCT01437540 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: aclidinium bromide/formoterol fumarate, formoterol fumarate
SMILES: COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Current or former cigarette smokers with a cigarette smoking history of at least 10
             pack-years

          -  A diagnosis of stable moderate to severe COPD and stable airway obstruction as defined
             by the Global Initiative for Chronic Obstructive Lung Disease guidelines and stable
             airway obstruction.

        Exclusion Criteria:

          -  Patients who have been hospitalized for an acute COPD exacerbation within three months
             prior to Visit 1

          -  Any respiratory tract infection (including the upper respiratory tract) or COPD
             exacerbation in the six weeks before Visit 1.

          -  Patients with any clinically significant respiratory conditions other than COPD

          -  Clinical history that suggests that the patient has asthma as opposed to COPD

          -  Chronic use of oxygen therapy ≥ 15 hours/day

          -  Patients with clinically significant cardiovascular conditions

          -  Patients with uncontrolled infection that may place the patient at risk resulting from
             human immunodeficiency virus (HIV), active hepatitis and/or patients with diagnosed
             active tuberculosis

          -  Patients with a history of hypersensitivity reaction to inhaled anticholinergics,

          -  Patients with Stage II hypertension, defined as systolic pressure of 160 and above,
             and/or diastolic pressure of 100 and above

          -  Current diagnosis of cancer other than basal or squamous cell skin cancer
Clinical trial NCT02441218 (phase 3, status: completed)
Conditions: chronic heart failure
ICD codes: I50.812, I50.22, I50.32, I50.813, I50.23, I50.33, I50.42
Drugs: ivabradine, placebo
SMILES: COC1=C(OC)C=C2[C@@H](CN(C)CCCN3CCC4=CC(OC)=C(OC)C=C4CC3=O)CC2=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Symptomatic Chronic heart failure (NYHA II, III or IV)

          -  Left ventricular systolic dysfunction (LVEF ≤ 35%)

          -  Sinus rhythm and resting heart rate ≥ 70 bpm

          -  Optimal and unchanged CHF medications or dosages

        Exclusion Criteria:

          -  Unstable condition within previous 4 weeks

          -  Myocardial infarction or coronary revascularisation within previous 2 months

          -  Stroke or transient cerebral ischaemia within previous 4 weeks

          -  Congenital heart disease

          -  Severe valvular disease

          -  Active myocarditis

          -  Permanent atrial fibrillation or flutter
Clinical trial NCT00516737 (phase 3, status: completed)
Conditions: migraine
ICD codes: G43.B1, G43.D1, G43.B0, G43.D0, G43.A1, G43.411, G43.419
Drugs: comparator: rizatriptan benzoate, comparator: placebo
SMILES: CN(C)CCC1=CNC2=C1C=C(CN1C=NC=N1)C=C2, CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion Criteria:

          -  Greater than one year history of migraine

          -  Attacks typically mild when they begin and progress to moderate or severe

          -  Experience 1-4 migraine attacks per month

        Exclusion Criteria:

          -  More than 15 headache days per month

          -  Heart disease

          -  Uncontrolled high blood pressure
Clinical trial NCT00145509 (phase 3, status: completed)
Conditions: bipolar disorder
ICD codes: F31.81, F31.89, F31.9, F25.0, F31.0, F31.31, F31.32
Drugs: asenapine, placebo
SMILES: OC(=O)\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have bipolar I disorder (current episode manic or mixed), be treated with lithium or
             valproic acid, and have completed the a 12-week lead-in trial

        Exclusion Criteria:

          -  Have an unstable medical condition or clinically significant laboratory abnormality.

          -  Have a primary diagnosis other than bipolar I disorder.
Clinical trial NCT00974818 (phase 3, status: terminated)
Conditions: bladder cancer
ICD codes: D30.3, C67.5, C67.9, C79.11, C67.0, C67.1, D41.4
Drugs: mitomycin c (mmc)
SMILES: CO[C@]12[C@H]3N[C@H]3CN1C1=C([C@H]2COC(N)=O)C(=O)C(N)=C(C)C1=O
Reason stopped: 
    lack of accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Age 18 years or older

          -  Patients must have pathologically confirmed non-muscle invasive urothelial bladder
             carcinoma by the Department of Pathology New York Presbyterian Hospital, Weill Medical
             College of Cornell University or Memorial Sloan Kettering Cancer Center or a
             documented past history of Ta or T1 non-muscle invasive urothelial bladder tumors.

          -  Intermediate Risk UBC patients: Recurrence Total Score = 1 to 9

        Exclusion Criteria:

          -  Any intravesical therapy within the past six months prior to current diagnosis

          -  Currently being treated or scheduled to have radiation treatment for bladder cancer
             during the study

          -  Scheduled to have surgery for bladder cancer during the study

          -  Currently being treated or scheduled to have treatment with any chemotherapeutic agent
             during the study
Clinical trial NCT00487240 (phase 3, status: completed)
Conditions: diabetes mellitus, type 1
ICD codes: E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: insulin lispro protamine suspension, insulin levemir
SMILES: OC(=O)[C@@H]1CCCN1, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Clinical diagnosis of type 1 diabetes for one year or more

          -  Age 18 years or older

          -  Body mass index (BMI) less than or equal to 35 kilograms per square meter (kg/m2)

          -  Have a hemoglobin A1c (HbA1c) 1.2 to 2.0 times the upper limit of the normal (ULN)
             reference range within 30 days prior to Visit 1 or collected and analyzed at a local
             laboratory at Visit 1

          -  As determined by the investigator, are capable and willing to do the following:

               -  perform self monitoring of blood glucose (SMBG),

               -  complete patient diaries as required for this protocol,

               -  use the insulin injection device(s) according to the instructions provided,

               -  are receptive to diabetes education,

               -  comply with the required study visits.

        Exclusion Criteria:

          -  Have taken any oral antihyperglycemic medications (OAMs) within 3 months prior to
             Visit 1.

          -  Have had more than one episode of severe hypoglycemia, as defined in the Abbreviations
             and Definitions section of the protocol, within 6 months prior to entry into the study

          -  Are pregnant or intend to become pregnant during the course of the study or are
             sexually active women of childbearing potential not actively practicing birth control
             by a method determined by the investigator to be medically acceptable or women who are
             breastfeeding

          -  Are receiving chronic (lasting longer than 14 consecutive days) systemic
             glucocorticoid therapy (excluding topical, intra-articular, intraocular, and inhaled
             preparations) or have received such therapy within the 4 weeks immediately preceding
             Visit 1.

          -  Have received treatment within the last 30 days with a drug that has not received
             regulatory approval for any indication at the time of study entry.
Clinical trial NCT00065806 (phase 3, status: completed)
Conditions: lupus erythematosus, systemic
ICD codes: M32.9, M32.0, M32.11, M32.12, M32.13, M32.14, M32.8
Drugs: atorvastatin, placebo atorvastatin
SMILES: CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Meets American College of Rheumatology (ACR) revised diagnostic guidelines for SLE

          -  Weight of 25 kg (55 lbs) or more

          -  Outpatient

          -  Ability to complete self-report questionnaires in either English or Spanish

          -  Willingness to comply with recommended diet

          -  Acceptable methods of contraception

        Exclusion Criteria:

          -  Drug-induced lupus

          -  Liver disease (ALT or aspartate aminotransferase greater than 2 X normal value)

          -  Myositis (CK greater than 3 X normal value)

          -  Inability to obtain adequate-quality IMT images

          -  Current use of oral or parenteral tacrolimus or cyclosporine

          -  Dialysis or serum creatinine reater than 2.5 mg/dL

          -  Active nephrotic syndrome (urinary protein greater than 3 g/24 h and serum albumin
             less than 2.3 g/dl)

          -  Total cholesterol greater than 350 mg/dL

          -  Xanthoma

          -  Familial hypercholesterolemia

          -  Pregnant or breastfeeding

          -  Use of estrogen-containing contraceptives (e.g., Lo-Ovral)

          -  Unable to adhere to study regimen

          -  Life-threatening non-SLE illness that would interfere with ability to complete the
             study

          -  Current drug or alcohol abuse

          -  Anticipated poor compliance

          -  Participation in another drug intervention study within 30 days of study enrollment
Clinical trial NCT00359762 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: exenatide, glimepiride
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosed with type 2 diabetes mellitus.

          -  Treated with diet and exercise and a stable, maximally tolerated dose of metformin for
             at least 3 months prior to screening.

          -  HbA1c >=6.5% and <=9.0%.

          -  Body Mass Index (BMI) >=25 kg/m^2 and <40 kg/m^2.

        Exclusion Criteria:

          -  Participated in an interventional medical, surgical, or pharmaceutical study within 30
             days prior to screening.

          -  Characteristics contraindicating metformin or glimepiride use.

          -  Receiving drugs that directly affect gastrointestinal motility.

          -  Receiving chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy.

          -  Have used any prescription drug to promote weight loss within 3 months prior to
             screening.

          -  Treated for longer than 2 weeks with any of the following medications within 3 months
             prior to screening: *insulin; *thiazolidinediones; *alpha-glucosidase inhibitors;
             *sulfonylurea; *meglitinides
Clinical trial NCT00488319 (phase 3, status: completed)
Conditions: schizophrenia, schizophrenic disorders, psychotic disorders, dementia praecox
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9, F23, F24, F12.159, F12.259, F12.150, F12.151, F12.250
Drugs: paliperidone er
SMILES: CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Meets the DSM-IV criteria for schizophrenia, otherwise physically healthy

          -  Weight >=63.9 pounds (29 kg)

          -  Must not be a danger to self or others and must have family support available to be
             maintained as outpatients

          -  Responsible adult must be available to accompany the patient to the investigational
             site at each visit.

        Exclusion Criteria:

          -  Meets the DSM-IV criteria for dissociative disorder, bipolar disorder, major
             depressive disorder, schizoaffective disorder, schizophreniform disorder, autistic
             disorder, or primary substance-induced psychotic disorder

          -  mild, moderate, or severe mental retardation

          -  History of substance dependence (including alcohol, but excluding nicotine and
             caffeine) according to the DSM-IV criteria in the 3 months before screening

          -  pregnancy (for females)

          -  History or presence of circumstances that may increase the risk of the occurrence of
             torsade de pointes or sudden death in association with the use of drugs that prolong
             the QTc interval.
Clinical trial NCT00359567 (phase 3, status: completed)
Conditions: chemotherapy-induced nausea and vomiting
ICD codes: D61.810
Drugs: palonosetron, granisetron hydrochloride
SMILES: [H][C@]12CCCC3=C1C(=CC=C3)C(=O)N(C2)[C@@H]1CN2CCC1CC2, CN1N=C(C(=O)N[C@@H]2C[C@@H]3CCC[C@H](C2)N3C)C2=C1C=CC=C2
Eligibility criteria:

        Inclusion Criteria:

          -  Patients aged 20 or more at the time when they give consent.

          -  Diagnosed as malignant disease.

          -  Be naive to chemotherapy or have been treated with single administration of anti-tumor
             drugs which are classified as low emetogenicity in the first edition of the 2006 NCCN
             Clinical Practice Guidelines.

          -  Cisplatin ≥50 mg/m2 Doxorubicin + cyclophosphamide: AC Epirubicin + cyclophosphamide:
             EC

          -  WBC ≥ 3000 /mm3 AST < 100 IU/L ALT < 100 IU/L Creatinine clearance ≥ 60 mL/min

          -  Performance Status : 0 - 2

        Exclusion Criteria:

          -  Severe (requiring hospitalization) and uncontrollable complications.

          -  Metastases to the brain which are symptomatic.

          -  Seizure disorder requiring anticonvulsant medication unless clinically stable and free
             of seizure activity.

          -  Symptomatic and invasive procedure indicated ascites or pleural effusion.

          -  Have either gastric outlet stenosis or intestinal obstruction.

          -  Have ongoing emesis or CTCAE grade 2 or greater nausea.

          -  QTc > 470 msec in the 12-lead ECG within eight days before registration.

          -  Known anaphylactic to ingredients of the study drug, namely palonosetron or
             granisetron hydrochloride injection, or other 5-HT3 receptor antagonists.

          -  Known anaphylactic to ingredients of dexamethasone.

          -  Pregnant women, breast-feeding women, or any male or female who are not willing to
             practice adequate contraception during the study period.
Clinical trial NCT01505426 (phase 3, status: completed)
Conditions: type ii diabetes mellitus
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65
Drugs: asp1941, metformin, placebo
SMILES: OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC=C(F)C(CC2=CC3=CC=CC=C3S2)=C1, CSCC[C@H](N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosed as type 2 diabetes mellitus patient at least 12 weeks before the study

          -  Stable diet and exercise program for at least 8 weeks before the study

          -  On a stable dose of at least 1500 mg/day metformin monotherapy or at least 1000 mg/day
             metformin monotherapy for the subject who can not titrate up to 1500 mg/day due to
             safety concern of metformin

          -  BMI of 20.0 to 45.0 kg/m2

          -  A HbA1c value between 7.0 and 10.0% at screening AND does not meet any of
             discontinuation criteria on fasting plasma glucose

        Exclusion Criteria:

          -  Type 1 diabetes mellitus

          -  Proliferative diabetic retinopathy

          -  Receiving insulin within 12 weeks prior to the study

          -  History of clinically significant renal disease(s)

          -  Significant dysuria caused by a neurogenic bladder or a benign prostate hypertrophy
             etc.

          -  Urinary tract infection or genital infection

          -  Continuous use of systemic corticosteroids, immunosuppressants, or loop diuretics

          -  History of cerebrovascular attack, unstable angina, myocardial infarction,
             angioplasty, serious cardiac diseases within 12 weeks prior to the study

          -  Severe infection, serious trauma, or perioperative subject

          -  Known or suspected hypersensitivity to ASP1941

          -  History of treatment with ASP1941

          -  Participated in another clinical study, postmarketing study or medical device study
             within 12 weeks before the study

          -  Serum creatinine value exceeding the upper limit of normal range

          -  Urinary microalbumin/urinary creatinine ratio >300 mg/g
Clinical trial NCT00143455 (phase 3, status: completed)
Conditions: small cell lung carcinoma
ICD codes: D02.20, D02.21, D02.22
Drugs: etoposide + cisplatin, irinotecan + cisplatin
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically proven Small Cell Lung Cancer (SCLC)

          -  WHO performance status : 0, 1

        Exclusion Criteria:

          -  No previous radiotherapy is allowed except on bone metastases when newly diagnosed.
             Radiotherapy is not allowed for vena cava syndrome, a stent is recommended ;

          -  No prior surgery on the primary tumor except for palliative purpose (stent for vena
             cava syndrome).
Clinical trial NCT01395888 (phase 3, status: completed)
Conditions: pulmonary disease, chronic obstructive
ICD codes: J44.9, J44.1, J44.0
Drugs: fluticasone furoate (ff, gw685698)/vilanterol (vi, gw642444) 100/25 mcg novel dry powder inhaler (ndpi), tiotropium
SMILES: [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1
Eligibility criteria:

        Inclusion Criteria:

          -  Type of subject: Outpatient

          -  Informed consent: Subjects must give their signed and dated written informed consent
             to participate.

          -  Gender: Male or female subjects.

          -  Age: greater then or equal to 40 years of age at Screening (Visit 1)

          -  COPD diagnosis: Subjects with a clinical history of COPD in accordance with the
             following definition by the American Thoracic Society (ATS) /European Respiratory
             Society(ERS).

          -  Subjects with a current or prior history ofgreater then or equal to 10 pack-years of
             cigarette smoking at Screening (Visit 1).

          -  Subjects with a measured post-albuterol/salbutamol FEV1 less then 70% of predicted at
             Screening (Visit 1).

          -  Subjects with a measured post-albuterol/salbutamol FEV1/FVC ratio of less then or
             equal to 0.70 at Screening (Visit 1).

          -  Exacerbation History: Subjects who have been hospitalised or have been treated with
             oral corticosteroids or antibiotics for their COPD within the last 3 years prior to
             Screening (V1).

          -  Baseline aPWV: subjects with a measured aPWV greater then 12.0 m/s at Screening (Visit
             1).

        Exclusion Criteria:

          -  Body Mass Index of less then or equal to 35
Clinical trial NCT00282464 (phase 3, status: completed)
Conditions: bipolar disorder
ICD codes: F31.81, F31.89, F31.9, F25.0, F31.0, F31.31, F31.32
Drugs: placebo, geodon (ziprasidone)
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects must have a primary diagnosis of Bipolar I Disorder, most recent episode
             depressed, with or without rapid cycling, without psychotic features, as defined in
             DSM-IV-TR (296.5X) and confirmed by a structured Mini International Neuropsychiatric
             Interview (MINI)

        Exclusion Criteria:

          -  Subjects with a DSM-IV TR diagnosis of schizophrenia (295.XX), schizoaffective
             disorder (295.70), schizophreniform disorder (295.40), delusional disorder (297.1), or
             psychotic disorder NOS (298.9).

          -  Subjects with other DSM-IV TR Axis I or Axis II disorder (in addition to Bipolar I
             disorder) are ineligible if the comorbid condition is clinically unstable, requires
             treatment, or has been a primary focus of treatment within the 6 month period prior to
             screening.
Clinical trial NCT00061919 (phase 3, status: completed)
Conditions: lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: carboplatin, etoposide & thalidomide, carboplatin, etoposide & placebo
SMILES: O=C1N(C2CCC(=O)NC2=O)C(=O)C2=CC=CC=C12, [H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H]
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed small cell lung cancer

               -  Limited or extensive stage disease

          -  No symptomatic brain metastases requiring immediate radiotherapy

        PATIENT CHARACTERISTICS:

        Age

          -  Over 18

        Performance status

          -  ECOG 0-3

        Life expectancy

          -  At least 8 weeks

        Hematopoietic

          -  Not specified

        Hepatic

          -  Not specified

        Renal

          -  Ethylenediamine tetraacetic acid (EDTA) clearance greater than 60 mL/min OR

          -  Creatinine clearance greater than 50 mL/min

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use 2 effective methods of contraception (including 1 highly
             effective method and 1 barrier method) during and for 4 weeks after study completion

          -  No other prior malignancy within the past 3 years except nonmelanoma skin cancer or
             early cervical cancer

          -  No significant medical condition or laboratory finding that would preclude study
             participation

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  No prior chemotherapy

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  See Disease Characteristics

          -  No prior radiotherapy

        Surgery

          -  Not specified
Clinical trial NCT02569996 (phase 3, status: completed)
Conditions: lymphoma, follicular
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: rituximab
SMILES: ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion Criteria:

          -  Adult participants greater than (>) 18 years of age

          -  Histologically confirmed follicular lymphoma Grade 1, 2, or 3a with lymph node biopsy
             within 4 months of induction treatment

          -  No previous anti-lymphoma treatment before induction chemotherapy (first-line-treated
             participants only are eligible)

          -  Verified complete or partial remission after first-line induction therapy including
             rituximab

        Exclusion Criteria:

          -  Grade 3b follicular lymphoma

          -  Transformation to high-grade lymphoma (except to Grade 3a) of previously existing
             follicular lymphoma

          -  Presence of central nervous system lymphoma

          -  Acquired immunodeficiency syndrome-related lymphoma

          -  Other primary malignancy (other than squamous cell cancer of the skin or in situ
             cancer of the cervix) for which the participant has not been disease-free for greater
             than or equal to (>=) 5 years